Maryam Sadat Mirlohi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maryam Sadat Mirlohi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ali Amin Asnafi
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 shared publications - Amir Reza Aref
Harvard Medical School
2 shared publications - Amir Seyfoori
Laboratory for Innovations in Microengineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada
2 shared publications - Hamid Yaghooti
Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University (TMU), Tehran, Iran
2 shared publications - Siamak Salami
Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Tooba Yousefi
Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran
2 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18 (2) , 022005
Tumor organoids on-a-chip and the role of AI in predictive oncology and personalized cancer medicine
The drug development process in cancer faces significant challenges due to high failure rates in translational studies despite promising in vitro results. Additionally, conventional animal models exhibit inherent limitations and ethical concerns, constraining their relevance to cancer studies. Recognizing the pivotal role of the tumor microenvironment (TME) on cancer development and treatment outcomes, recent advancements in 3D microfluidic devices and tumor-on-a-chip models enabled researchers to explore the TME with enhanced accuracy and reliability, yielding novel insights. Notably, the emergence of physiological tumor models, particularly 3D models such as organoids derived from human tissues, provides a more accurate representation of in vivo tumor features. Moreover, 3D tumor models hold promise for diverse applications, including high-throughput drug testing, disease modeling, and regenerative medicine. Meanwhile, combining artificial intelligence (AI) with patient-derived tumor organoids has become a key strategy in predictive oncology and personalized cancer treatment. Furthermore, incorporating quantitative systems pharmacology and physiologically based pharmacokinetic modeling, and pharmacokinetics/pharmacodynamics analysis with generative AI (Gen-AI) has revolutionized predictive oncology by enabling precise simulations of drug interactions and patient-specific responses, thereby enhancing the predictive accuracy of personalized cancer treatments. These advanced methodologies harness the power of AI algorithms to analyze intricate datasets derived from patient-specific tumor organoids. Moreover, the predictive modeling capabilities of Gen-AI facilitate the development of personalized treatment strategies customized for each patient, thereby revolutionizing oncology practice. This review explores the synergistic impact of tumor-on-a-chip models, organoids derived from patient tumors, and Gen-AI. Together, these technologies mark a significant advancement in precision medicine, offering promising opportunities to improve therapeutic effectiveness and treatment outcomes in cancer care.
- 17 March 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18 (2) , 022005
Open AccessTumor organoids on-a-chip and the role of AI in predictive oncology and personalized cancer medicine
The drug development process in cancer faces significant challenges due to high failure rates in translational studies despite promising in vitro results. Additionally, conventional animal models exhibit inherent limitations and ethical concerns, constraining their relevance to cancer studies. Recognizing the pivotal role of the tumor microenvironment (TME) on cancer development and treatment outcomes, recent advancements in 3D microfluidic devices and tumor-on-a-chip models enabled researchers to explore the TME with enhanced accuracy and reliability, yielding novel insights. Notably, the emergence of physiological tumor models, particularly 3D models such as organoids derived from human tissues, provides a more accurate representation of in vivo tumor features. Moreover, 3D tumor models hold promise for diverse applications, including high-throughput drug testing, disease modeling, and regenerative medicine. Meanwhile, combining artificial intelligence (AI) with patient-derived tumor organoids has become a key strategy in predictive oncology and personalized cancer treatment. Furthermore, incorporating quantitative systems pharmacology and physiologically based pharmacokinetic modeling, and pharmacokinetics/pharmacodynamics analysis with generative AI (Gen-AI) has revolutionized predictive oncology by enabling precise simulations of drug interactions and patient-specific responses, thereby enhancing the predictive accuracy of personalized cancer treatments. These advanced methodologies harness the power of AI algorithms to analyze intricate datasets derived from patient-specific tumor organoids. Moreover, the predictive modeling capabilities of Gen-AI facilitate the development of personalized treatment strategies customized for each patient, thereby revolutionizing oncology practice. This review explores the synergistic impact of tumor-on-a-chip models, organoids derived from patient tumors, and Gen-AI. Together, these technologies mark a significant advancement in precision medicine, offering promising opportunities to improve therapeutic effectiveness and treatment outcomes in cancer care.
- Open Access
Advances and Challenges in KRAS Mutation Detection and Clinical Implications
Aberrant activation of the RAS signaling pathway is a halmark of various cancers. This activation, is often caused by mutations in RAS genes or other pathway components and, drivesi uncontrolled cell growth and proliferation. Studies have demonstrated that certain codon mutations can significantly influence the clinical outcomes of cancer patients. Historically, KRAS was considered “undruggable”; however, recent advancements in drug discovery have led to the development of promising KRAS inhibitors. Accurately identifying the specific type of KRAS mutation in a patient is essential for making optimal treatment decisions. Several methods have been developed for detecting KRAS mutations to address this need, focusing on creating robust, rapid, sensitive, accurate, and cost-effective approaches, particularly for point-of-care applications. Starting with the Ras family and RASopathies, this review provides a comprehensive overview of KRAS mutation detection methods, ranging from research-use-only techniques to in vitro diagnostic-certified tests. Published results are critically evaluated in terms of accuracy, sensitivity, cost, throughput, and suitability for various sample types and clinical settings. This, offers researchers and clinicians an up-to-date resource for.
Open AccessAdvances and Challenges in KRAS Mutation Detection and Clinical Implications
Aberrant activation of the RAS signaling pathway is a halmark of various cancers. This activation, is often caused by mutations in RAS genes or other pathway components and, drivesi uncontrolled cell growth and proliferation. Studies have demonstrated that certain codon mutations can significantly influence the clinical outcomes of cancer patients. Historically, KRAS was considered “undruggable”; however, recent advancements in drug discovery have led to the development of promising KRAS inhibitors. Accurately identifying the specific type of KRAS mutation in a patient is essential for making optimal treatment decisions. Several methods have been developed for detecting KRAS mutations to address this need, focusing on creating robust, rapid, sensitive, accurate, and cost-effective approaches, particularly for point-of-care applications. Starting with the Ras family and RASopathies, this review provides a comprehensive overview of KRAS mutation detection methods, ranging from research-use-only techniques to in vitro diagnostic-certified tests. Published results are critically evaluated in terms of accuracy, sensitivity, cost, throughput, and suitability for various sample types and clinical settings. This, offers researchers and clinicians an up-to-date resource for.
- Open Access
- 24 November 2025
- Published by MDPI AG in Biomimetics
- Vol. 10 (12) , 796
Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs
Traditional animal-based preclinical models, including xenografts and genetically engineered mice, have been used for assessing pharmacodynamics, toxicity, efficacy, and safety for decades. Despite their limited ability to mimic human tumor heterogeneity, immune interactions, and microenvironmental complexity, over 90% of oncology candidates that succeed in animal studies fail in clinical trials. The New Approach Methodologies (NAMs), which include patient-derived organoids, organ-on-chip platforms, and AI-driven computational models, provide human-relevant solutions that can improve predictive validity, mechanistic insight, and ethics. Through these technologies, it will be possible to replicate tumor biology specific to patients, to support co-clinical trial designs, and to facilitate biomarker discovery while reducing animal testing. Several recent regulatory reforms, including the Food and Drug Administration (FDA) Modernization Act 2.0 and the European Medicines Agency’s NAM qualification framework, have established clear pathways for the integration of validated NAMs into preclinical drug evaluation. Critically evaluating the scientific rationale, comparative performance, and regulatory context of key NAM platforms in oncology, this review highlights opportunities for synergistic integration, technical refinement, and global harmonization in order to accelerate the development of clinically effective cancer therapeutics based on preclinical findings.
- 24 November 2025
- Published by MDPI AG in Biomimetics
- Vol. 10 (12) , 796
Open AccessIntegrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs
Traditional animal-based preclinical models, including xenografts and genetically engineered mice, have been used for assessing pharmacodynamics, toxicity, efficacy, and safety for decades. Despite their limited ability to mimic human tumor heterogeneity, immune interactions, and microenvironmental complexity, over 90% of oncology candidates that succeed in animal studies fail in clinical trials. The New Approach Methodologies (NAMs), which include patient-derived organoids, organ-on-chip platforms, and AI-driven computational models, provide human-relevant solutions that can improve predictive validity, mechanistic insight, and ethics. Through these technologies, it will be possible to replicate tumor biology specific to patients, to support co-clinical trial designs, and to facilitate biomarker discovery while reducing animal testing. Several recent regulatory reforms, including the Food and Drug Administration (FDA) Modernization Act 2.0 and the European Medicines Agency’s NAM qualification framework, have established clear pathways for the integration of validated NAMs into preclinical drug evaluation. Critically evaluating the scientific rationale, comparative performance, and regulatory context of key NAM platforms in oncology, this review highlights opportunities for synergistic integration, technical refinement, and global harmonization in order to accelerate the development of clinically effective cancer therapeutics based on preclinical findings.
- 20 February 2022
- Published by Knowledge E DMCC in Journal of Advanced Biomedical Sciences
Characterization of Common β-Thalassemia Major Mutations in Southwest Iran with Respect to Biochemical Parameters, Oxidative Status and Complications
Background & Objective: Beta-thalassemia are among the most common autosomal recessive genetic disorders in Iran, especially in Khuzestan province. Beta-thalassemia exhibits significant phenotype heterogeneity and there are currently more than 200 known mutations in this region. Oxidative stress exacerbates multiple disorders, including thalassemia, an inherited hemolytic anemia caused by globin gene mutations. We aim to characterize significant mutations of widespread β-thalassemia in south-western Iran with respect to biochemical parameters, oxidative status and complications of diseases. Material & method: Forty-five patients, aged between 15-35 years with β-thalassemia major were selected. The patients were receiving regular blood transfusion and chelation therapy and have been previously characterized to bear beta globin gene mutations. The subjects’ medical histories were documented by review of previous medical records. We also determined biochemical parameters including glycemic and iron indices, hepatic and renal function tests, oxidative stress markers and levels of advanced glycation end product species (Carboxy methyl lysine and Pentosidin). Results: The most common mutation was found to be CD36/37(28.9%) followed by IVSII-1, and IVSI-110. Values of iron indices were significantly different in various mutation groups. Carboxy methyl lysine and pentosidine were found to be higher in the β-thalassemia patients with IVSII-1 and IVSI-110, respectively. Also sLOX-1 was found to be significantly higher in IVSI-110 group. Complications of the disease were differently presented in mutation groups and hemochromatosis, hepatomegaly, and diabetes were among the most common problems. Conclusion: About 72 % of β-thalassemia major cases in southwest Iran result form 3 common mutations with different clinical and laboratory presentations. Molecular genetic testing can be helpful to evaluate the patients’ situation.
- 20 February 2022
- Published by Knowledge E DMCC in Journal of Advanced Biomedical Sciences
Characterization of Common β-Thalassemia Major Mutations in Southwest Iran with Respect to Biochemical Parameters, Oxidative Status and Complications
Background & Objective: Beta-thalassemia are among the most common autosomal recessive genetic disorders in Iran, especially in Khuzestan province. Beta-thalassemia exhibits significant phenotype heterogeneity and there are currently more than 200 known mutations in this region. Oxidative stress exacerbates multiple disorders, including thalassemia, an inherited hemolytic anemia caused by globin gene mutations. We aim to characterize significant mutations of widespread β-thalassemia in south-western Iran with respect to biochemical parameters, oxidative status and complications of diseases. Material & method: Forty-five patients, aged between 15-35 years with β-thalassemia major were selected. The patients were receiving regular blood transfusion and chelation therapy and have been previously characterized to bear beta globin gene mutations. The subjects’ medical histories were documented by review of previous medical records. We also determined biochemical parameters including glycemic and iron indices, hepatic and renal function tests, oxidative stress markers and levels of advanced glycation end product species (Carboxy methyl lysine and Pentosidin). Results: The most common mutation was found to be CD36/37(28.9%) followed by IVSII-1, and IVSI-110. Values of iron indices were significantly different in various mutation groups. Carboxy methyl lysine and pentosidine were found to be higher in the β-thalassemia patients with IVSII-1 and IVSI-110, respectively. Also sLOX-1 was found to be significantly higher in IVSI-110 group. Complications of the disease were differently presented in mutation groups and hemochromatosis, hepatomegaly, and diabetes were among the most common problems. Conclusion: About 72 % of β-thalassemia major cases in southwest Iran result form 3 common mutations with different clinical and laboratory presentations. Molecular genetic testing can be helpful to evaluate the patients’ situation.
- 9 January 2018
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (4) , 679-684
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major
The impaired biosynthesis of the β-globin chain in β-thalassemia leads to the accumulation of unpaired alpha globin chains, failure in hemoglobin formation, and iron overload due to frequent blood transfusion. Iron excess causes oxidative stress and massive tissue injuries. Advanced glycation end products (AGEs) are harmful agents, and their production accelerates in oxidative conditions. This study was conducted on 45 patients with major β-thalassemia who received frequent blood transfusions and chelation therapy and were compared to 40 healthy subjects. Metabolic parameters including glycemic and iron indices, hepatic and renal functions tests, oxidative stress markers, and AGEs (carboxymethyl-lysine and pentosidine) levels were measured. All parameters were significantly increased in β-thalassemia compared to the control except for glutathione levels. Blood glucose, iron, serum ferritin, non-transferrin-bound iron (NTBI), MDA, soluble form of low-density lipoprotein receptor, glutathione peroxidase, total reactive oxygen species (ROS), and AGE levels were significantly higher in the β-thalassemia patients. Iron and ferritin showed a significant positive correlation with pentosidine (P < 0.01) but not with carboxymethyl-lysine. The NTBI was markedly increased in the β-thalassemia patients, and its levels correlated significantly with both carboxymethyl-lysine and pentosidine (P < 0.05). Our findings confirm the oxidative status generated by the iron overload in β-thalassemia major patients and highlight the enhanced formation of AGEs, which may play an important role in the pathogenesis of β-thalassemia major.
- 9 January 2018
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (4) , 679-684
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major
The impaired biosynthesis of the β-globin chain in β-thalassemia leads to the accumulation of unpaired alpha globin chains, failure in hemoglobin formation, and iron overload due to frequent blood transfusion. Iron excess causes oxidative stress and massive tissue injuries. Advanced glycation end products (AGEs) are harmful agents, and their production accelerates in oxidative conditions. This study was conducted on 45 patients with major β-thalassemia who received frequent blood transfusions and chelation therapy and were compared to 40 healthy subjects. Metabolic parameters including glycemic and iron indices, hepatic and renal functions tests, oxidative stress markers, and AGEs (carboxymethyl-lysine and pentosidine) levels were measured. All parameters were significantly increased in β-thalassemia compared to the control except for glutathione levels. Blood glucose, iron, serum ferritin, non-transferrin-bound iron (NTBI), MDA, soluble form of low-density lipoprotein receptor, glutathione peroxidase, total reactive oxygen species (ROS), and AGE levels were significantly higher in the β-thalassemia patients. Iron and ferritin showed a significant positive correlation with pentosidine (P < 0.01) but not with carboxymethyl-lysine. The NTBI was markedly increased in the β-thalassemia patients, and its levels correlated significantly with both carboxymethyl-lysine and pentosidine (P < 0.05). Our findings confirm the oxidative status generated by the iron overload in β-thalassemia major patients and highlight the enhanced formation of AGEs, which may play an important role in the pathogenesis of β-thalassemia major.